Healthcare >> Analyst Interviews >> January 25, 2010
Blurred Lines Between Life Sciences & Diagnostics – Stephen D. Simpson – Northland Securities, Inc.
Stephen D. Simpson, CFA, joined Northland Securities in December 2008 as a Senior Analyst covering medical technology companies. Mr. Simpson has extensive experience in the health care sector, having worked as a sell-side Equity Analyst at Piper Jaffray and more recently as a Consultant to the health care industry, focusing on the life sciences and metabolic/endocrine disease markets. He has a B.S.L.A. in Japanese from Georgetown University and holds a Series 7, Series 63, Series 86 and Series 87 license. Profile
TWST: You cover both the medical devices and the life sciences companies. Tell us specifically what you cover in that space.
Mr. Simpson: The stocks I cover are Bio-Rad (BIO), Cardiovascular Systems